Header

UZH-Logo

Maintenance Infos

Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland


Sulz, Michael C; Frei, Remus; Meyenberger, Christa; Bauerfeind, Peter; Semadeni, Gian-Marco; Gubler, Christoph (2014). Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland. Endoscopy, 46(7):619-624.

Abstract

Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic agent recently introduced for the management of upper gastrointestinal bleeding (GIB). To date, there is little experience with this fairly new hemostatic tool. The aim of this case series was to reflect the use and effectiveness of Hemospray as a treatment option in GIB in everyday clinical practice at two tertiary referral centers. Consecutive patients (n = 16) with active GIB of various origins were treated with Hemospray. The rate of successful initial hemostasis was 93.75 % (15 /16; salvage therapy 92.85 % [13/14]; monotherapy 100 % [2 /2]). The rebleeding rate within 7 days was 12.5 % (2/16). One patient, in whom interventional radiology also failed, had to undergo surgery as salvage therapy. The effectiveness of Hemospray in the management of GIB in various clinical situations is promising. Future multicenter randomized prospective trials for clearly defined bleeding situations are needed for greater generalizability of case series findings.

Abstract

Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic agent recently introduced for the management of upper gastrointestinal bleeding (GIB). To date, there is little experience with this fairly new hemostatic tool. The aim of this case series was to reflect the use and effectiveness of Hemospray as a treatment option in GIB in everyday clinical practice at two tertiary referral centers. Consecutive patients (n = 16) with active GIB of various origins were treated with Hemospray. The rate of successful initial hemostasis was 93.75 % (15 /16; salvage therapy 92.85 % [13/14]; monotherapy 100 % [2 /2]). The rebleeding rate within 7 days was 12.5 % (2/16). One patient, in whom interventional radiology also failed, had to undergo surgery as salvage therapy. The effectiveness of Hemospray in the management of GIB in various clinical situations is promising. Future multicenter randomized prospective trials for clearly defined bleeding situations are needed for greater generalizability of case series findings.

Statistics

Citations

16 citations in Web of Science®
21 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

108 downloads since deposited on 11 Feb 2015
62 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:July 2014
Deposited On:11 Feb 2015 11:39
Last Modified:08 Dec 2017 10:24
Publisher:Georg Thieme Verlag
ISSN:0013-726X
Publisher DOI:https://doi.org/10.1055/s-0034-1365505
PubMed ID:24770964

Download

Download PDF  'Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 56kB
View at publisher